{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Cisneros JM"],"funding":["FP7 Health"],"pagination":["383"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC6883535"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["23(1)"],"pubmed_abstract":["Background
Colistin is recommended in the empirical treatment of ventilator-associated pneumonia (VAP) with a high prevalence of carbapenem-resistant gram-negative bacilli (CR-GNB). However, the efficacy and safety of colistin are not well defined.Methods
A multicenter prospective randomized trial conducted in 32 European centers compared the efficacy and safety of colistin (4.5 million unit loading dose followed by a maintenance dose of 3 million units every 8 h) versus meropenem (2 g every 8 h), both in combination with levofloxacin (500 mg every 12 h) for 7-14 days in patients with late VAP. Between May 2012 and October 2015, 232 patients were randomly assigned to the 2 treatment groups. The primary endpoint was mortality at 28 days after randomization in the microbiolog"],"journal":["Critical care (London, England)"],"pubmed_title":["Colistin versus meropenem in the empirical treatment of ventilator-associated pneumonia (Magic Bullet study): an investigator-driven, open-label, randomized, noninferiority controlled trial."],"pmcid":["PMC6883535"],"funding_grant_id":["278232"],"pubmed_authors":["Gonzalez V","Sierra R","Lepe JA","Polanco MJ","Pozo JC","Malachias S","Seller G","Lopez MD","Antonelli M","Nakos G","Estella A","Bello G","Garnacho-Montero J","de la Torre MV","Magic Bullet Working Group WP1","Ferrer R","Cisneros JM","Leal R","Koutsoukou A","Pneumatikos I","Jimenez-Jorge S","Gutierrez-Pizarraya A","Zakinthinos S","Komnos A","Alvarez-Rocha L","Espinosa MC","De Roberts E","Diaz-Miguel RO","Ramirez P","Di Gravio V","Allegue JM","Herrera-Gutierrez ME","Zaragoza R","Zakynthinos E","Matthaiou DK","Bitsan M","Dominguez PJ","De Pascale G","Puppo A","Rosso-Fernandez CM","Villarreal E","Zafeiridis T","Fernandez-Hinojosa E","Dimopoulos G","Roca-Oporto C","Gonzalez A","Vidal P"],"additional_accession":[]},"is_claimable":false,"name":"Colistin versus meropenem in the empirical treatment of ventilator-associated pneumonia (Magic Bullet study): an investigator-driven, open-label, randomized, noninferiority controlled trial.","description":"Background
Colistin is recommended in the empirical treatment of ventilator-associated pneumonia (VAP) with a high prevalence of carbapenem-resistant gram-negative bacilli (CR-GNB). However, the efficacy and safety of colistin are not well defined.Methods
A multicenter prospective randomized trial conducted in 32 European centers compared the efficacy and safety of colistin (4.5 million unit loading dose followed by a maintenance dose of 3 million units every 8 h) versus meropenem (2 g every 8 h), both in combination with levofloxacin (500 mg every 12 h) for 7-14 days in patients with late VAP. Between May 2012 and October 2015, 232 patients were randomly assigned to the 2 treatment groups. The primary endpoint was mortality at 28 days after randomization in the microbiolog","dates":{"release":"2019-01-01T00:00:00Z","publication":"2019 Nov","modification":"2026-05-04T11:32:32.693Z","creation":"2020-05-21T20:49:56Z"},"accession":"S-EPMC6883535","cross_references":{"pubmed":["31779711"],"doi":["10.1186/s13054-019-2627-y"]}}